hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06360731, orgStudyIdInfo id: 1018, briefTitle: The Effect of 4-7-8 Breathing Exercise Technique on Tinnitus, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Ege University, class: OTHER, descriptionModule briefSummary: The goal of this study is to evaluate the effect of 4-7-8 breathing exercise on tinnitus handicap, psychological factors and sleep quality.There will be a parallel-group randomized controlled trial study and consists of two groups.Both groups will receive 1 hour of informative session on tinnitus and the experimental group will also perform 4-7-8 breathing exercises for 6 weeks. Visual analog scale, tinnitus handicap inventory, insomnia severity index, trait anxiety inventory, and perceived stress scale will be applied before and after the application., conditionsModule conditions: Tinnitus, Subjective, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study employs a parallel group randomised controlled trial design., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: In the study, patients do not know which group they were in. Therefore, blinding is performed among the participants. To prevent bias in the study, blinding is also performed between the researchers. Researchers (S.B. and A.O. from both clinics) make the pre- and post-test evaluations without knowing which group the patients are in., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: 4-7-8 breathing exercise technique and informative session on tinnitus, interventions name: Informative session on tinnitus, outcomesModule primaryOutcomes measure: Visual Analog Scale (VAS), primaryOutcomes measure: Visual Analog Scale (VAS), primaryOutcomes measure: Tinnitus Handicap Inventory (THI), primaryOutcomes measure: Tinnitus Handicap Inventory (THI), primaryOutcomes measure: Insomnia severity index (ISI), primaryOutcomes measure: Insomnia severity index (ISI), primaryOutcomes measure: Perceived stress scale -10 (PSS-10), primaryOutcomes measure: Perceived stress scale -10 (PSS-10), primaryOutcomes measure: Trait Anxiety Scale (TAS), primaryOutcomes measure: Trait Anxiety Scale (TAS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Gokce Saygi Uysal, city: Ankara, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, locations facility: Audiology Unit of the Department of Otorhinolaryngology, Ege University Faculty of Medicine Hospital, city: Izmir, country: Turkey, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False
protocolSection identificationModule nctId: NCT06360718, orgStudyIdInfo id: CHLA-23-00170, briefTitle: Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-03, primaryCompletionDateStruct date: 2025-05-15, completionDateStruct date: 2025-05-15, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Children's Hospital Los Angeles, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to measure the effects of using a storybook versus standard child life intervention with parents of children newly diagnosed with leukemia on parental stress.The main questions it aims to answer are:* What effect will the storybook have on parent/legal guardian stress at three timepoints: baseline, discharge, and follow up?* Will this storybook impact parent/legal guardian comfort levels and improve their child's understanding?Participants will be asked to complete surveys at three timepoints, prior to and following child life intervention and about 3.5 months later. During child life interventions, participants will receive resources and support to explain leukemia to their school aged, 3-16-year-old, child (patient or sibling).Researchers will compare Intervention and Control Groups to see if parental stress is lower in those who received the storybook in addition to the standard child life intervention versus the standard child life intervention alone., conditionsModule conditions: Leukemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: "Who is Luke Eemia?" Storybook, outcomesModule primaryOutcomes measure: Parental Stress, prior to and following child life intervention, secondaryOutcomes measure: Parent perception of the child's stress, secondaryOutcomes measure: Parent's Comfort Explaining Aspects of Leukemia Diagnosis, secondaryOutcomes measure: Parent comfort, readiness, and importance, explaining aspects of the diagnosis at the discharge (1-week post baseline)., secondaryOutcomes measure: Parental Impression of the Storybook Tool using a Likert scale (1-week post baseline)., eligibilityModule sex: ALL, minimumAge: 3 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Children's Hospital Los Angeles, status: RECRUITING, city: Los Angeles, state: California, zip: 90027, country: United States, contacts name: Erin Shields, MA, role: CONTACT, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06360705, orgStudyIdInfo id: CVVD003, briefTitle: StrataMGT for the Treatment of Vulvar Lichen Sclerosus, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Center for Vulvovaginal Disorders, class: OTHER, collaborators name: Stratpharma AG, descriptionModule briefSummary: This study is designed to evaluate the efficacy and safety of StrataMGT for the treatment of vulvar lichen sclerosus., conditionsModule conditions: Vulvar Lichen Sclerosus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 5, type: ESTIMATED, armsInterventionsModule interventions name: StrataMGT, outcomesModule primaryOutcomes measure: Histopathologic Inflammation, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centers for Vulvovaginal Disorders, status: RECRUITING, city: New York, state: New York, zip: 10036, country: United States, contacts name: Andrew Goldstein, MD, role: CONTACT, phone: 4102790209, email: obstetrics@yahoo.com, contacts name: Andrew Goldstein, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Leia Mitchell, PA-C, MMSc, MSc, role: SUB_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06360692, orgStudyIdInfo id: Marta Lluesma Vidal Carden, briefTitle: Impact of Nipple Micropigmentation in Mastectomized Women, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Cardenal Herrera University, class: OTHER, descriptionModule briefSummary: This will be a multicenter prospective descriptive case series study following a cohort.The micropigmentation/tattoo procedure will be carried out following the protocol established in each center (see annex x). The present investigation only involves measuring the impact that this technique has on the patients by collecting data in digital format before and after the CAP micropigmentation/tattoo that motivated their visit to the clinical service.CAP micropigmentation/tattooing is usually performed between 6 and 12 months after the breast reconstructive surgery has been completed, sufficient time for healing to complete and the breast to stabilize, although it can be performed from 2 months after the intervention. Nurses are responsible for performing micropigmentation/tattooing of the areola and nipple in mastectomized women., conditionsModule conditions: Body Image, conditions: Female Sexual Function, conditions: Self Esteem, conditions: Intimacy With Your Partner, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, outcomesModule primaryOutcomes measure: Body imagen, secondaryOutcomes measure: Self-esteem, secondaryOutcomes measure: Sexual Function, secondaryOutcomes measure: Intimacy with the partner, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06360679, orgStudyIdInfo id: CIP000004, briefTitle: Clinical Feasibility Study of the BariTon™ System in Obese or Overweight Patients., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-29, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: BariaTek Medical, class: INDUSTRY, descriptionModule briefSummary: Safety and efficacy evaluation of the BariTon™, BariaTek Medical gastric restriction and biliodigestive diversion device., conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Endoscopic gastric restriction and biliodigestive diversion, outcomesModule primaryOutcomes measure: Safety of the BariTon™, primaryOutcomes measure: Safety of the BariTon™, secondaryOutcomes measure: Safety of the BariTon™, secondaryOutcomes measure: Safety of the BariTon™, secondaryOutcomes measure: Efficacy of the BariTon™, secondaryOutcomes measure: Efficacy of the BariTon™, secondaryOutcomes measure: Efficacy of the BariTon™, secondaryOutcomes measure: Efficacy of the BariTon™, secondaryOutcomes measure: Efficacy of the BariTon™, secondaryOutcomes measure: Efficacy of the BariTon™, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: BMI Clinic Double Bay, status: RECRUITING, city: Sydney, state: New South Wales, zip: 2028, country: Australia, contacts name: Adrian Sartoretto, Dr, role: CONTACT, phone: 0290534688, phoneExt: 61, email: info@bmiclinic.com.au, geoPoint lat: -33.86785, lon: 151.20732, locations facility: BMI Clinic Liverpool, status: RECRUITING, city: Sydney, state: New South Wales, zip: 2170, country: Australia, contacts name: Adrian Sartoretto, Dr, role: CONTACT, phone: 0290534688, phoneExt: 61, email: info@bmiclinic.com.au, geoPoint lat: -33.86785, lon: 151.20732, hasResults: False
protocolSection identificationModule nctId: NCT06360666, orgStudyIdInfo id: Neurax1, briefTitle: Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia, acronym: NEURAX, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2022-10-01, primaryCompletionDateStruct date: 2024-01-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Asst Melegnano e Martesana, class: OTHER_GOV, descriptionModule briefSummary: The goal of this observational study is to learn about postoperative mortality and postoperative length of stay outcomes after abdominal laparoscopic major surgery. The main question it aims to answer is:Does general anesthesia lower complications compared to loco-regional anesthesia (keeping the patient spontaneously breathing and sedated) in laparoscopic abdominal major surgery? Participants are followed for neurological sequelae for 90 days following surgery, conditionsModule conditions: Mortality, conditions: Surgical Complication, conditions: Neurological Complication, conditions: Respiratory Complication, conditions: Cardiovascular Complication, conditions: Nephrotoxicity, conditions: Metabolic Complication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Mortality, primaryOutcomes measure: Morbidity, secondaryOutcomes measure: Surgical revisions, secondaryOutcomes measure: organ dysfunctions, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ASST Melegnano e Martesana - Ospedale Vizzolo Predabissi, city: Vizzolo Predabissi, state: Milan, zip: 20070, country: Italy, geoPoint lat: 45.35587, lon: 9.34815, hasResults: False
protocolSection identificationModule nctId: NCT06360653, orgStudyIdInfo id: 76CIVICO2023, briefTitle: a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer, acronym: SISTER-RAY, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: ARNAS Civico Di Cristina Benfratelli Hospital, class: OTHER, descriptionModule briefSummary: The primary endpoint of the present prospective study is to assess the outcomes in terms of acute toxicity of post-operative stereotactic radiotherapy for endometrial cancer, conditionsModule conditions: Endometrial Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Stereotactic Post-operative Radiotherapy for Endometrial Cancer, outcomesModule primaryOutcomes measure: Acute G3 or higher Gastrointestinal and Genitourinary Toxicity, secondaryOutcomes measure: Late Gastrointestinal and Genitourinary Toxicity, secondaryOutcomes measure: Distant Progression Free Survival, secondaryOutcomes measure: Local Control, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Overall Quality of Life, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ARNAS Civico Hospital, city: Palermo, state: PA, zip: 90100, country: Italy, contacts name: FRANCESCO CUCCIA, MD, role: CONTACT, phone: +393334393336, email: francesco.cuccia@arnascivico.it, geoPoint lat: 38.13205, lon: 13.33561, hasResults: False
protocolSection identificationModule nctId: NCT06360627, orgStudyIdInfo id: 2022_D0008, briefTitle: Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-20, primaryCompletionDateStruct date: 2027-03-31, completionDateStruct date: 2027-12-01, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: University of Zurich, class: OTHER, descriptionModule briefSummary: Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT, conditionsModule conditions: Radiation Exposure, conditions: Lung Embolism, conditions: Lung Cancer, conditions: Pneumonia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Computed Tomography, outcomesModule primaryOutcomes measure: Dose Reduction by new scanner, primaryOutcomes measure: stable Image Quality in reduced dose scans, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Zurich - Diagnostic Radiology, status: RECRUITING, city: Zurich, zip: 8091, country: Switzerland, contacts name: Thomas Frauenfelder, PD MD, role: CONTACT, phone: 0041442551111, email: thomas.frauenfelder@usz.ch, contacts name: Marga Rominger, Prof MD, role: CONTACT, phone: 0041442551111, email: marga.rominger@usz.ch, contacts name: Thomas Frauenfelder, PD MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.36667, lon: 8.54999, hasResults: False
protocolSection identificationModule nctId: NCT06360601, orgStudyIdInfo id: 36264PR589/3/24, briefTitle: Intravenous Labetalol Versus Hydralazine in Preeclampsia, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome, conditionsModule conditions: Preeclampsia Severe, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Labetalol Injection, interventions name: HydrALAZINE Injection, outcomesModule primaryOutcomes measure: Cerebral blood flow, eligibilityModule sex: FEMALE, minimumAge: 25 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Medicine, city: Tanta, zip: 3511, country: Egypt, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06360588, orgStudyIdInfo id: NCI-2024-01141, secondaryIdInfos id: NCI-2024-01141, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: EAY131-Z1G, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: EAY131-Z1G, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2018-06-19, primaryCompletionDateStruct date: 2024-11-15, completionDateStruct date: 2024-11-15, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth., conditionsModule conditions: Malignant Solid Neoplasm, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Copanlisib, interventions name: Radiologic Examination, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: 6-month progression-free survival (PFS) rate, secondaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ECOG-ACRIN Cancer Research Group, city: Philadelphia, state: Pennsylvania, zip: 19103, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06360575, orgStudyIdInfo id: NCI-2024-01127, secondaryIdInfos id: NCI-2024-01127, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: EAY131-C2, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: EAY131-C2, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2016-05-30, primaryCompletionDateStruct date: 2024-11-15, completionDateStruct date: 2024-11-15, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II MATCH treatment trial tests how well crizotinib works to treat patients with cancers with MET exon 14 deletion genetic changes. Crizotinib is in a group of medications called tyrosine kinase inhibitors. It works by blocking enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow., conditionsModule conditions: Advanced Lymphoma, conditions: Advanced Malignant Solid Neoplasm, conditions: Refractory Lymphoma, conditions: Refractory Malignant Solid Neoplasm, conditions: Refractory Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Crizotinib, interventions name: Radiologic Examination, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: 6-month progression-free survival (PFS) rate, secondaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ECOG-ACRIN Cancer Research Group, city: Philadelphia, state: Pennsylvania, zip: 19103, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False